Despite continuous advances in understanding the underlying pathogenesis of
hyperexcitable networks and lowered seizure thresholds, the treatment of epilepsy remains …

Based on promising preclinical evidence, microglial P2X7 has increasingly being
recognized as a target for therapeutic intervention in neurological and psychiatric diseases …

Stress exposure is considered to be the main environmental cause associated with the
development of depression. Due to the limitations of currently available antidepressants, a …

Background and Purpose Refractory status epilepticus is a clinical emergency associated
with high mortality and morbidity. Increasing evidence suggests neuroinflammation …

Despite the progress made in the development of new antiepileptic drugs (AEDs), the
biggest challenges that epilepsy presents to drug development have remained unchanged …

Epilepsy, characterized by recurrent spontaneous seizures, is a heterogeneous group of
brain diseases affecting over 70 million people worldwide. Major challenges in the …

Temporal lobe epilepsy (TLE) is one of the most common types of focal epilepsy,
characterized by recurrent spontaneous seizures originating in the temporal lobe (s), with …

Abstract Treatment of epilepsy remains a clinical challenge, with> 30% of patients not
responding to current antiseizure drugs (ASDs). Moreover, currently available ASDs are …

The P2X7 receptor is an ATP-gated nonselective cation channel that has been linked to a
number of inflammatory diseases. Activation of the P2X7 receptor by elevated levels of ATP …

The purinergic receptor P2X7 is expressed in neural and immune cells known to be involved
in neurological diseases. Its ligand, ATP, is a signaling molecule that can act as a …